12
Participants
Start Date
July 31, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
March 1, 2017
CABOZANTINIB
Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
gemcitabine
Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
University of Michigan Comprehensive Cancer Center, Ann Arbor
University of Michigan Rogel Cancer Center
OTHER